---
title: "503A Compounding"
definition: "A category of US pharmacy compounding regulated under section 503A of the Federal Food, Drug, and Cosmetic Act. Permits state-licensed pharmacies to compound drugs for individual patients with a valid prescription, under specific conditions."
url: https://retatrutide.med/glossary/compounding-503a
category: "general"
source: retatrutide.med
sourceType: "glossary term"
license: CC-BY-NC-SA-4.0
canonical: https://retatrutide.med/glossary/compounding-503a
---
## 503A Compounding

Section 503A of the Federal Food, Drug, and Cosmetic Act creates a regulatory category for state-licensed pharmacies that compound drugs for individual identified patients pursuant to a valid prescription. 503A compounding is exempt from certain FDA requirements (most notably new-drug approval, cGMP manufacturing standards in their entirety, and labeling rules) that apply to commercially manufactured drugs. The trade-off is strict conditions: the drug must be compounded for a specific patient, the bulk drug substance must be on an FDA-approved list or meet specific qualifying criteria, and the pharmacy must operate under state board of pharmacy oversight.

The related section 503B regulates "outsourcing facilities" — registered facilities that may compound drugs without individual prescriptions but must comply with more cGMP-like requirements and FDA inspection.

For investigational compounds such as retatrutide, neither 503A nor 503B compounding is legally permitted. The bulk drug substance must be on an applicable FDA-approved list (or meet specific monograph/listing criteria) for compounding to be legal — and retatrutide does not meet those criteria. Retatrutide is investigational; it has never been FDA-approved; it has never been on the FDA drug shortage list (the temporary mechanism that briefly allowed semaglutide and tirzepatide compounding); and it is not the subject of an applicable USP or NF monograph.

The FDA has acted on this point. In September 2025 the agency issued more than fifty warning letters to compounders selling products labeled as retatrutide. In December 2025 the FDA issued a warning letter to Darmerica, an active pharmaceutical ingredient importer, citing cGMP violations, distribution to 503A compounding pharmacies, and failure to list all drugs distributed into interstate commerce. The legal and safety implications: any product marketed as retatrutide outside of an authorized clinical trial is unapproved, not subject to the manufacturing controls of approved drugs, and may not even contain the active ingredient claimed.